10.18
price down icon5.57%   -0.60
after-market アフターアワーズ: 10.48 0.30 +2.95%
loading
前日終値:
$10.78
開ける:
$10.38
24時間の取引高:
280.27K
Relative Volume:
0.80
時価総額:
$62.26M
収益:
$55.54M
当期純損益:
$-180.40M
株価収益率:
-12.92
EPS:
-0.7877
ネットキャッシュフロー:
$-170.32M
1週間 パフォーマンス:
-14.09%
1か月 パフォーマンス:
-27.41%
6か月 パフォーマンス:
-61.40%
1年 パフォーマンス:
-94.91%
1日の値動き範囲:
Value
$9.7744
$10.66
1週間の範囲:
Value
$9.7744
$12.14
52週間の値動き範囲:
Value
$9.104
$309.60

Gossamer Bio Inc Stock (GOSS) Company Profile

Name
名前
Gossamer Bio Inc
Name
セクター
Healthcare (1060)
Name
電話
(858) 684-1300
Name
住所
3115 MERRYFIELD ROW, SAN DIEGO, CA
Name
職員
162
Name
Twitter
@GossamerBio
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
GOSS's Discussions on Twitter

Compare GOSS vs VRTX, MRNA, REGN, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GOSS icon
GOSS
Gossamer Bio Inc
10.18 66.91M 55.54M -180.40M -170.32M -0.7877
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
505.64 127.93B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
196.48 79.40B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
742.12 81.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
928.44 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
200.87 43.93B 742.00K -1.37B -1.07B -7.0731

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2026-02-24 ダウングレード Barclays Overweight → Equal Weight
2026-02-24 ダウングレード Leerink Partners Outperform → Market Perform
2026-02-24 ダウングレード Wedbush Outperform → Neutral
2026-01-28 開始されました Barclays Overweight
2025-09-10 アップグレード UBS Neutral → Buy
2025-07-14 開始されました Scotiabank Sector Outperform
2024-06-25 開始されました Oppenheimer Outperform
2024-04-05 再開されました Wedbush Outperform
2023-07-27 ダウングレード UBS Buy → Neutral
2023-03-07 ダウングレード Raymond James Outperform → Mkt Perform
2023-03-01 開始されました Guggenheim Neutral
2022-12-07 ダウングレード Barclays Overweight → Equal Weight
2022-12-07 ダウングレード JP Morgan Neutral → Underweight
2022-12-07 ダウングレード SMBC Nikko Outperform → Neutral
2022-10-20 開始されました Goldman Buy
2022-09-21 開始されました JP Morgan Neutral
2022-09-19 開始されました Wedbush Outperform
2022-04-18 開始されました Raymond James Outperform
2022-04-06 開始されました UBS Buy
2022-01-10 アップグレード SMBC Nikko Neutral → Outperform
2021-11-09 再開されました Cantor Fitzgerald Overweight
2021-09-21 再開されました Piper Sandler Overweight
2020-06-29 開始されました H.C. Wainwright Buy
2020-04-22 開始されました Piper Sandler Overweight
2020-02-27 開始されました Barclays Overweight
2019-12-03 再開されました BofA/Merrill Buy
2019-10-30 開始されました Berenberg Buy
2019-03-05 開始されました Barclays Overweight
2019-03-05 開始されました BofA/Merrill Buy
2019-03-05 開始されました Evercore ISI Outperform
2019-03-05 開始されました SVB Leerink Outperform
すべてを表示

Gossamer Bio Inc (GOSS) 最新ニュース

pulisher
Sep 30, 2026

Gossamer Bio Inc (GOSS) Stock Price Target & Forecast - TradingKey

Sep 30, 2026
pulisher
Sep 28, 2026

A shareholder falls below 5% in Gossamer Bio (GOSS) after a reverse stock split. - Stock Titan

Sep 28, 2026
pulisher
Sep 28, 2026

Gossamer Bio regains Nasdaq compliance after 1-for-80 reverse stock split - TradingView

Sep 28, 2026
pulisher
Sep 25, 2026

Form 4 Gossamer Bio Inc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026
pulisher
Sep 25, 2026

GOSSAMER BIO INC (GOSS) Stock Chart - ChartMill

Sep 25, 2026
pulisher
Sep 25, 2026

At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

At Gossamer Bio (GOSS), director Daniel Thomas O's options carry a $10.99 exercise price. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Gossamer Bio (GOSS) grants a director options priced at $10.99 per share - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

At Gossamer Bio (GOSS), director Drynan Skye receives stock options priced at $10.99 per share. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Director Russell J. Cox receives Gossamer Bio (GOSS) options with a $10.99-per-share exercise price. - Stock Titan

Sep 25, 2026
pulisher
Sep 25, 2026

Gossamer Bio grants director options on 10,000 shares - Stock Titan

Sep 25, 2026
pulisher
Sep 24, 2026

Gossamer Bio stock falls 5.99 percent after FDA filing - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 24, 2026

Gossamer Bio submits seralutinib NDA after Phase 3 endpoint miss - Mugglehead Investment Magazine

Sep 24, 2026
pulisher
Sep 23, 2026

Gossamer Bio Submits First NDA for Seralutinib to FDA for Pulmonary Arterial Hypertension - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging Valuation Landscape - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertension - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio stock rises on FDA filing for PAH drug - Investing.com India

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio Files New Drug Application for Seralutinib - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio stock rises on FDA filing for PAH drug By Investing.com - Investing.com Nigeria

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio submits NDA for seralutinib in PAH treatment By Investing.com - Investing.com Australia

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio (GOSS) Files NDA for Seralutinib Amid Low Valuation and Mixed Financial Signals - GuruFocus

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio submits NDA for seralutinib in PAH treatment - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Yahoo Finance

Sep 23, 2026
pulisher
Sep 22, 2026

Gossamer Bio : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com

Sep 22, 2026
pulisher
Sep 22, 2026

Gossamer Bio stock gains 12.04 percent in the latest quote - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 21, 2026

Equity in earnings of Gossamer Bio, Inc. – SWB:4GB0 - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

Total assets of Gossamer Bio, Inc. – SWB:4GB0 - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

GOSS Maintained by HC Wainwright & Co. -- Price Target Raised to $90 - GuruFocus

Sep 21, 2026
pulisher
Sep 21, 2026

GOSS Price Target Soars to $90 After Reverse Split; Market Prici - GuruFocus

Sep 21, 2026
pulisher
Sep 21, 2026

H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Cuts Target Price to $90 - Moomoo

Sep 21, 2026
pulisher
Sep 21, 2026

HC Wainwright & Co. maintains Buy rating on Gossamer Bio, $90 price target - TradingView

Sep 21, 2026
pulisher
Sep 19, 2026

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits

Sep 19, 2026
pulisher
Sep 19, 2026

Cash flow from financing activities of Gossamer Bio, Inc. – MUN:4GB0 - TradingView

Sep 19, 2026
pulisher
Sep 18, 2026

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill

Sep 18, 2026
pulisher
Sep 17, 2026

Gossamer Bio Adds Veteran Investor to Board of Directors - The Globe and Mail

Sep 17, 2026
pulisher
Sep 17, 2026

Gossamer Bio (NASDAQ: GOSS) Schedules October 27 Vote on Warrants and Preferred Stock Conversion - kalkinemedia.com

Sep 17, 2026
pulisher
Sep 17, 2026

Cash flow from financing activities of Gossamer Bio, Inc. – LSX:A42M0V - TradingView

Sep 17, 2026
pulisher
Sep 16, 2026

Total assets of Gossamer Bio, Inc. – LSX:A42M0V - TradingView

Sep 16, 2026
pulisher
Sep 16, 2026

Gossamer Bio appoints Greg Ciongoli to board of directors By Investing.com - Investing.com Nigeria

Sep 16, 2026
pulisher
Sep 16, 2026

Gossamer Bio appoints Greg Ciongoli to board of directors - Investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

Gossamer Bio, Inc. Announces Appointment of Greg Ciongoli to Board of Directors and Audit Committee, Effective September 16, 2026 - marketscreener.com

Sep 16, 2026
pulisher
Sep 16, 2026

Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Yahoo Finance

Sep 16, 2026
pulisher
Sep 14, 2026

Gossamer Bio Inc to discuss its business update Transcript - GuruFocus

Sep 14, 2026
pulisher
Sep 12, 2026

Gossamer Bio Inc (FRA:4GB0) Stock Price & 30 Year Financial Data - GuruFocus

Sep 12, 2026
pulisher
Sep 12, 2026

Gossamer Bio (FRA:4GB0) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2026) - GuruFocus

Sep 12, 2026
pulisher
Sep 12, 2026

Gossamer Bio (FRA:4GB0) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2026) - GuruFocus

Sep 12, 2026
pulisher
Sep 12, 2026

Gossamer Bio Inc (FRA:4GB0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Sep 12, 2026
pulisher
Sep 11, 2026

Form 8K Gossamer Bio Inc For: 11 September By Investing.com - Investing.com Nigeria

Sep 11, 2026
pulisher
Sep 11, 2026

Gossamer Bio completes 1-for-80 reverse stock split By Investing.com - Investing.com Australia

Sep 11, 2026
pulisher
Sep 11, 2026

Gossamer Bio Implements 1-for-80 Reverse Stock Split to Address Nasdaq Compliance - citybiz

Sep 11, 2026

Gossamer Bio Inc (GOSS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$95.25
price down icon 0.50%
$34.75
price down icon 2.20%
$56.76
price up icon 0.57%
$224.41
price up icon 0.21%
ONC ONC
$364.02
price up icon 0.34%
$200.87
price up icon 0.50%
大文字化:     |  ボリューム (24 時間):